For EAU22, the ESU organised 56 courses covering 17 topics wherein 150 distinguished experts from 23 countries will lead the courses and mentor participants. Read on to know more about the newest additions to the course programme on prostate cancer.
ESU course 1 Theranostics in prostate cancer
Chair and presenter: Prof. Dr. Boris Hadaschik (DE)
Presenters: Prof. Wim Oyen (NL) and Prof. Philip P. Cornford (GB)
The term “theranostics” is the combination of two words: therapeutic (thera) and diagnostic (nostic), which allows the combination of diagnosis, treatment, and continuous follow up of a disorder.
Based on nuclear medicine technologies, theranostics was introduced in the management of prostate cancer (PCa). The concept of theranostics has the potential to change PCa management and become an essential part of the urological armamentarium.
The aim of this course is to provide an in depth overview of theranostics and to critically asses its performance, efficacy and limitations. During the course, participants will enrich their knowledge on various PSMA-PET tracers and radioligands; staging of primary disease and biochemical recurrence with PET imaging; radioligand treatment for metastatic PCa, and more.
ESU course 56 Prostate cancer challenges and controversies from guidelines to real-world
Chair and presenter: Prof. Francisco Gómez Veiga (ES)
Fellow presenters: Prof. Anders Bjartell (SE), Prof. Dr. Nicolas Mottet (FR), and Assoc. Prof. Rafael Sanchez-Salas (FR)
This ESU course will offer insights on how to minimise unnecessary biopsies through optimal use of prostate-specific antigen (PSA), new biomarkers, and magnetic resonance imaging (MRI). Participants will also learn how to stratify factors according to various approaches; how to select which at-risk patients to treat; and management after local progression.
With eye-opening discussions on real cases and multiple-choice questions, this dynamic course will provide vital information on the diagnosis and treatment of advanced tumours, metastatic naïve, non-metastatic castration-resistant prostate cancer (nmCRPC), or metastatic castrate-resistant prostate cancer (mCRPC) including the latest advances for precision and personalised treatments. The course will examine new alternatives in detail, as well as, cost-effectiveness.
The new ESU course will also comprise relevant topics such as:
*This is an excerpt from the article “ESU courses at EAU22: Prime updates, best practices, and solid fundamentals”, click here to read the whole article and how to enrol to ESU courses taking place during the congress.
Visit the EAU22 congress website for the whole scientific programme.